Vind

Vind is a biotechnology company focused on the discovery and development of molecular glues to enable targeted protein degradation (TPD). The company utilizes a proprietary platform to identify small molecules that can induce the degradation of disease-causing proteins by facilitating their interaction with E3 ligases. This approach is designed to target proteins that were previously considered "undruggable" by traditional small molecule inhibitors. Vind's primary therapeutic focus areas include oncology and immunology, where TPD offers the potential for highly selective and potent treatments. Based in South San Francisco, the company is backed by prominent investors such as GV and Lightspeed Venture Partners.